BerGenBio

Report Publication Announcement • Aug 4, 2021

BERGENBIO ASA: INVITATION TO PRESENTATION OF SECOND QUARTER AND HALF YEAR 2021 RESULTS

Bergen, Norway, 4 August 2021 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, will be announcing its results for the second quarter and half year 2021 on Tuesday 17 August 2021. A webcast presentation by BerGenBio's senior management team will take place at 10:00 am CET.

The live webcast link will be available at www.bergenbio.com in the Investors/Financial Reports section. A recording will be available shortly after the webcast has finished.

The second quarter report and presentation will be available on the Company's website in the Investors/Financial Reports section from 7:00 am CET the same day.

-Ends-

Contacts

Richard Godfrey CEO, BerGenBio ASA ir@bergenbio.com

Rune Skeie, CFO, BerGenBio ASA rune.skeie@bergenbio.com

Media Relations

Mary-Jane Elliott, Chris Welsh, Lucy Featherstone, Carina Jurs

Consilium Strategic Communications bergenbio@consilium-comms.com +44 20 3709 5700

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including immune-evasive, therapy resistant cancers. The company's proprietary lead candidate, bemcentinib, is a potentially first-in-class selective AXL inhibitor in a broad phase II clinical development programme focused on combination and single agent therapy in cancer, leukaemia and COVID-19. A first-in-class functional blocking anti-AXL antibody, tilvestamab, is undergoing phase I clinical testing. In parallel, BerGenBio is developing a companion diagnostic test to identify patient populations most likely to benefit from AXL inhibition: this is expected to facilitate more efficient registration trials supporting a precision medicine-based commercialisation strategy.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more information, visit www.bergenbio.com